Administration of a monomeric CCL2 variant to EAE mice inhibits inflammatory cell recruitment and protects from demyelination and axonal loss

[1]  M. Mack,et al.  An engineered monomer of CCL2 has anti‐inflammatory properties emphasizing the importance of oligomerization for chemokine activity in vivo , 2008, Journal of leukocyte biology.

[2]  A. Proudfoot,et al.  The use of chemokine antagonists in EAE models , 2008, Journal of Neuroimmunology.

[3]  G. Comi,et al.  IL4 gene delivery to the CNS recruits regulatory T cells and induces clinical recovery in mouse models of multiple sclerosis , 2008, Gene Therapy.

[4]  S. Brod,et al.  Ingested (oral) alpha-MSH inhibits acute EAE , 2008, Journal of Neuroimmunology.

[5]  Y. Talke,et al.  Targeting of Gr-1+,CCR2+ monocytes in collagen-induced arthritis. , 2007, Arthritis and rheumatism.

[6]  E. Waubant.  Emerging therapies for MS. , 2007, Revue neurologique.

[7]  H. Lassmann,et al.  Temporal expression and cellular origin of CC chemokine receptors CCR1, CCR2 and CCR5 in the central nervous system: insight into mechanisms of MOG-induced EAE , 2007, Journal of Neuroinflammation.

[8]  J. Correale,et al.  The blood–brain-barrier in multiple sclerosis: Functional roles and therapeutic targeting , 2007, Autoimmunity.

[9]  A. L. Teixeira,et al.  Effect of the treatment with methylprednisolone on the cerebrospinal fluid and serum levels of CCL2 and CXCL10 chemokines in patients with active multiple sclerosis , 2006, Acta neurologica Scandinavica.

[10]  R. Ransohoff,et al.  The many roles of chemokines and chemokine receptors in inflammation. , 2006, The New England journal of medicine.

[11]  M. Teixeira,et al.  CCL2 and CCL5 mediate leukocyte adhesion in experimental autoimmune encephalomyelitis—an intravital microscopy study , 2005, Journal of Neuroimmunology.

[12]  M. Pender,et al.  Chemokines and chemokine receptors: potential therapeutic targets in multiple sclerosis. , 2004, Current drug targets. Inflammation and allergy.

[13]  F. Sellebjerg,et al.  Chemokine CCL2 and chemokine receptor CCR2 in early active multiple sclerosis , 2004, European journal of neurology.

[14]  B. Rollins,et al.  Monocyte Chemoattractant Protein‐1 (CCL2) in Inflammatory Disease and Adaptive Immunity: Therapeutic Opportunities and Controversies , 2003, Microcirculation.

[15]  H. Amemiya,et al.  Amelioration of Experimental Autoimmune Encephalomyelitis in Lewis Rats by FTY720 Treatment , 2003, Journal of Pharmacology and Experimental Therapeutics.

[16]  Timothy N. C. Wells,et al.  Glycosaminoglycan binding and oligomerization are essential for the in vivo activity of certain chemokines , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[17]  R. Ransohoff,et al.  The role of MCP-1 (CCL2) and CCR2 in multiple sclerosis and experimental autoimmune encephalomyelitis (EAE). , 2003, Seminars in immunology.

[18]  R. Ransohoff,et al.  Experimental autoimmune encephalomyelitis: CC chemokine receptor expression by trafficking cells. , 2002, Journal of autoimmunity.

[19]  D. Bourdette,et al.  Alpha lipoic acid inhibits T cell migration into the spinal cord and suppresses and treats experimental autoimmune encephalomyelitis , 2002, Journal of Neuroimmunology.

[20]  Y. Jee,et al.  Upregulation of monocyte chemotactic protein-1 and CC chemokine receptor 2 in the central nervous system is closely associated with relapse of autoimmune encephalomyelitis in Lewis rats , 2002, Journal of Neuroimmunology.

[21]  D. Mahad,et al.  Expression of chemokines in the CSF and correlation with clinical disease activity in patients with multiple sclerosis , 2002, Journal of neurology, neurosurgery, and psychiatry.

[22]  D. Galimberti,et al.  IP-10 and MCP-1 levels in CSF and serum from multiple sclerosis patients with different clinical subtypes of the disease , 2002, Journal of the Neurological Sciences.

[23]  F. Sellebjerg,et al.  Distinct chemokine receptor and cytokine expression profile in secondary progressive MS , 2001, Neurology.

[24]  R. Bergamaschi,et al.  Serum and CSF levels of MCP-1 and IP-10 in multiple sclerosis patients with acute and stable disease and undergoing immunomodulatory therapies , 2001, Journal of Neuroimmunology.

[25]  B. Rollins,et al.  Absence of Monocyte Chemoattractant Protein 1 in Mice Leads to Decreased Local Macrophage Recruitment and Antigen-Specific T Helper Cell Type 1 Immune Response in Experimental Autoimmune Encephalomyelitis , 2001, The Journal of experimental medicine.

[26]  Y. Itoyama,et al.  Chemokine receptor expression on T cells in blood and cerebrospinal fluid at relapse and remission of multiple sclerosis: imbalance of Th1/Th2-associated chemokine signaling , 2001, Journal of Neuroimmunology.

[27]  L. Santambrogio,et al.  Modulation of experimental autoimmune encephalomyelitis: effect of altered peptide ligand on chemokine and chemokine receptor expression , 2000, Journal of Neuroimmunology.

[28]  W. Kuziel,et al.  Cc Chemokine Receptor 2 Is Critical for Induction of Experimental Autoimmune Encephalomyelitis , 2000, The Journal of experimental medicine.

[29]  H. Weiner,et al.  Leukocyte recruitment during onset of experimental allergic encephalomyelitis is CCR1 dependent , 2000, European journal of immunology.

[30]  J. Newcombe,et al.  Expression of the β-chemokine receptors CCR2, CCR3 and CCR5 in multiple sclerosis central nervous system tissue , 2000, Journal of Neuroimmunology.

[31]  Toshiyuki Yamamoto,et al.  Monocyte Chemoattractant Protein-1 Enhances Gene Expression and Synthesis of Matrix Metalloproteinase-1 in Human Fibroblasts by an Autocrine IL-1α Loop1 , 2000, The Journal of Immunology.

[32]  A. Zlotnik,et al.  Chemokines: a new classification system and their role in immunity. , 2000, Immunity.

[33]  K. Jarnagin,et al.  Identification of residues in the monocyte chemotactic protein-1 that contact the MCP-1 receptor, CCR2. , 1999, Biochemistry.

[34]  I. Charo.  CCR2: from cloning to the creation of knockout mice. , 1999, Chemical immunology.

[35]  H. Weiner,et al.  CCR5(+) and CXCR3(+) T cells are increased in multiple sclerosis and their ligands MIP-1alpha and IP-10 are expressed in demyelinating brain lesions. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[36]  K. Jarnagin,et al.  Monomeric Monocyte Chemoattractant Protein-1 (MCP-1) Binds and Activates the MCP-1 Receptor CCR2B* , 1998, The Journal of Biological Chemistry.

[37]  R. Strieter,et al.  Acute and relapsing experimental autoimmune encephalomyelitis are regulated by differential expression of the CC chemokines macrophage inflammatory protein-1α and monocyte chemotactic protein-1 , 1998, Journal of Neuroimmunology.

[38]  A. Rot.  Neutrophil attractant/activation protein‐1 (interleukin‐8) induces in vitro neutrophil migration by haptotactic mechanism , 1993, European journal of immunology.

[39]  Matthias Mack,et al.  Modulating CCR2 and CCL2 at the blood-brain barrier: relevance for multiple sclerosis pathogenesis. , 2006, Brain : a journal of neurology.

[40]  R. Ransohoff,et al.  The expression and function of chemokines involved in CNS inflammation. , 2006, Trends in pharmacological sciences.

[41]  Y. Shugart,et al.  Association of haplotypes in the beta-chemokine locus with multiple sclerosis. , 2005, European journal of human genetics : EJHG.

[42]  G. Martino,et al.  Cytokine gene delivery into the central nervous system using intrathecally injected nonreplicative viral vectors. , 2003, Methods in molecular biology.

[43]  T. Yamamoto,et al.  Monocyte chemoattractant protein-1 enhances gene expression and synthesis of matrix metalloproteinase-1 in human fibroblasts by an autocrine IL-1 alpha loop. , 2000, Journal of immunology.

[44]  G. Comi,et al.  Central nervous system delivery of interleukin 4 by a nonreplicative herpes simplex type 1 viral vector ameliorates autoimmune demyelination. , 1998, Human gene therapy.